Proportion of first-time testers, participation of men, and proportion of participants newly tested HIV-positive with advanced disease.

<p>All aORs and adjusted <i>p</i>-values are adjusted for cluster effect. In non-stratified analyses, aORs and <i>p</i>-values are also adjusted for gender and age group. Missing data for gender: 6; missing data for age group: 11.</p><p>NA, not applicable; OR, odds ratio.</p><p>Proportion of first-time testers, participation of men, and proportion of participants newly tested HIV-positive with advanced disease.</p

Consort chart of the study.

<p>One health center with its catchment area formed a cluster. ITT, intention to treat.</p

Characteristics of randomized clusters and baseline characteristics of study participants.

¶<p>Data derived from national HTC registers of the 12 health centers in the study area.</p>§<p><i>p</i>-Value for age group distribution: 0.88.</p><p>*<i>p</i>-Value for gender distribution: 0.044.</p><p>IQR, interquartile range.</p><p>Characteristics of randomized clusters and baseline characteristics of study participants.</p

Patient-flow in the study.

<p>92 (69%) of the patients initially eligible for the study received a VL-result and were included in the final analysis. VL: viral load. ART: Anti-retroviral Therapy. WHO: World Health Organization.</p

Characteristics of the 92 patients included in the analysis.

<p>IQR: inter-quartile range. ART: Anti-retroviral therapy. WHO: World Health Organization. HAART: Highly active anti-retroviral therapy. PMTCT: Prevention of mother-to-child transmission.</p

Positive predictive value of the clinical score and the WHO criteria.

<p> <b>Clinical score and WHO-criteria as predictors for a detectable viral load (≥40 copies) or viral failure (≥5’000 copies) among the 92 patients analysed for the study.</b></p><p>VL: Viral load. WHO: World Health Organization.</p

The clinical score used in this study to predict viral failure.

<p>The score was originally developed in a Cambodian cohort <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0047937#pone.0047937-Lynen1" target="_blank">[9]</a>.</p>*<p>HAART, Highly Active Antiretroviral Therapy.</p>¶<p>Comparing current hemoglobin level to a documented hemoglobin measurement 3 to 9 months ago.</p